MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Metagenomi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.81+0.03 (+3.55%)
Close on Oct 19, 2026
- Market cap
- $30.57M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Metagenomi Therapeutics has not reported a dividend
No dividend per share appears in Metagenomi Therapeutics's annual filings since fiscal 2022.